JP2018513155A - セリバンツマブを用いた併用療法 - Google Patents

セリバンツマブを用いた併用療法 Download PDF

Info

Publication number
JP2018513155A
JP2018513155A JP2017553926A JP2017553926A JP2018513155A JP 2018513155 A JP2018513155 A JP 2018513155A JP 2017553926 A JP2017553926 A JP 2017553926A JP 2017553926 A JP2017553926 A JP 2017553926A JP 2018513155 A JP2018513155 A JP 2018513155A
Authority
JP
Japan
Prior art keywords
hrg
patient
nsclc
serivantumab
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017553926A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513155A5 (https=
Inventor
バンバン アディウィジャヤ，
バンバン アディウィジャヤ，
アコス クジベレ，
アコス クジベレ，
レイチェル シー． ネーリング，
レイチェル シー． ネーリング，
ギャビン マクベス，
ギャビン マクベス，
Original Assignee
メリマック ファーマシューティカルズ インコーポレーティッド
メリマック ファーマシューティカルズ インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メリマック ファーマシューティカルズ インコーポレーティッド, メリマック ファーマシューティカルズ インコーポレーティッド filed Critical メリマック ファーマシューティカルズ インコーポレーティッド
Publication of JP2018513155A publication Critical patent/JP2018513155A/ja
Publication of JP2018513155A5 publication Critical patent/JP2018513155A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017553926A 2015-04-17 2016-04-15 セリバンツマブを用いた併用療法 Withdrawn JP2018513155A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149271P 2015-04-17 2015-04-17
US62/149,271 2015-04-17
PCT/US2016/027933 WO2016168730A1 (en) 2015-04-17 2016-04-15 Combination treatments with seribantumab

Publications (2)

Publication Number Publication Date
JP2018513155A true JP2018513155A (ja) 2018-05-24
JP2018513155A5 JP2018513155A5 (https=) 2019-05-23

Family

ID=55854801

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017553926A Withdrawn JP2018513155A (ja) 2015-04-17 2016-04-15 セリバンツマブを用いた併用療法

Country Status (13)

Country Link
US (1) US20160303232A1 (https=)
EP (1) EP3283068A1 (https=)
JP (1) JP2018513155A (https=)
KR (1) KR20170137886A (https=)
CN (1) CN107750165A (https=)
AU (1) AU2016248329A1 (https=)
CA (1) CA2983008A1 (https=)
EA (1) EA201792294A1 (https=)
HK (2) HK1248539A1 (https=)
IL (1) IL255092A0 (https=)
MA (1) MA45420A (https=)
SG (1) SG11201708491PA (https=)
WO (1) WO2016168730A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017161009A1 (en) * 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc. Dosage and administration of combination therapies comprising targeted antibodies uses and methods of treatment
WO2018140821A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
CA3104868A1 (en) 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング， インコーポレイテッド 肝臓特異的Ｗｎｔシグナル増強分子およびその使用
CN115976196B (zh) * 2022-12-16 2024-12-06 深圳市人民医院 ErbB3作为肺动脉高压生物标志物和治疗靶点的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102580084B (zh) * 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
DK2500439T4 (da) 2005-06-20 2017-11-13 Advanced Cell Diagnostics Inc Kits og produkter til detektering af nukleinsyrer i individuelle celler og til identifikation af sjældne celler fra store heterogene cellepopulationer
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
WO2010019952A2 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
EP2571992B1 (en) 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
PH12013500064A1 (en) * 2010-07-09 2013-03-11 Exelixis Inc Combinations of kinase inhibitors for the treatment of cancer
WO2012103341A1 (en) 2011-01-27 2012-08-02 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid stage tumors using anti-erbb3 antibodies
US20140134170A1 (en) 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
MX2013010444A (es) * 2011-03-15 2014-03-21 Merrimack Pharmaceuticals Inc Superar la resistencia a inhibidores de la via erbb.
AU2012275850A1 (en) 2011-06-30 2013-03-21 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-ErbB3 antibodies in combination with paclitaxel for treatment of gynecological cancers
AU2012294326A1 (en) 2011-08-10 2013-03-21 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy
WO2013138371A1 (en) 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
SG11201602291TA (en) * 2013-09-30 2016-04-28 Daiichi Sankyo Co Ltd Nucleic acid biomarker and use thereof
EP3087394A2 (en) * 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies

Also Published As

Publication number Publication date
US20160303232A1 (en) 2016-10-20
KR20170137886A (ko) 2017-12-13
EA201792294A1 (ru) 2018-03-30
HK1248539A1 (zh) 2018-10-19
CA2983008A1 (en) 2016-10-20
EP3283068A1 (en) 2018-02-21
HK1250626A1 (zh) 2019-01-11
WO2016168730A1 (en) 2016-10-20
MA45420A (fr) 2019-05-01
SG11201708491PA (en) 2017-11-29
CN107750165A (zh) 2018-03-02
AU2016248329A1 (en) 2017-11-09
IL255092A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
Chuang et al. ERBB2-mutated metastatic non–small cell lung cancer: response and resistance to targeted therapies
JP2018513155A (ja) セリバンツマブを用いた併用療法
RU2480211C2 (ru) Лечение рака молочной железы с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами
Santin et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study
Moehler et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
Nogi et al. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer
JP2020172487A (ja) トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法
US20230310455A1 (en) Combination therapies for treatment of her2 cancer
CN109310754A (zh) 使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法
CN101918003A (zh) 单独使用parp抑制剂或与抗肿瘤剂组合治疗子宫癌和卵巢癌
JP2019518426A (ja) がんの診断及び治療方法
AU2019350581B2 (en) Methods of treatment of cancer comprising Cdc7 inhibitors
JP2019521971A (ja) がんの処置
Hamberg et al. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial
KR20200014298A (ko) Her2 양성 암의 치료
KR20210106483A (ko) Mdm2 억제제를 위한 확장된 저용량 요법
TW202241442A (zh) Ｋｒａｓ ｇ１２ｃ抑制劑在治療癌症中之用途
Frank et al. A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study
He et al. The ability of clinically relevant chemotherapeutics to induce immunogenic cell death in squamous cell carcinoma
Ocean et al. Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach
Chilimoniuk et al. Molecular methods for increasing the effectiveness of ovarian cancer treatment: A systematic review
KR20200110452A (ko) 담도암을 치료하기 위한 방법 및 조합 요법
Liu et al. A phase 1 trial of the PARP inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
Wang et al. Palbociclib regulates the expression of dihydrofolate reductase and the cell cycle to inhibit t (11; 14) multiple myeloma
Roviello et al. A phase Ib open-label study to assess the safety and tolerability of everolimus in combination with eribulin in triple-negative breast cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190412

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190826